With GENE to GMP™ we can help you achieve faster time-to-market, lower manufacturing costs and can rescue your promising drug candidates.
In June 2017, JSR Life Sciences acquired Selexis as part of JSR’s commitment
to offer industry partners best-in-class contract development manufacturing (CDMO) services. Selexis SA and KBI Biopharma, which was acquired by JSR in 2015, have joined forces
to provide industry partners “GENE to GMP in 9 Months” —
the most robust and fastest service offering for the biopharmaceutical industry.
The Selexis SUREtechnology Platform™ facilitates the rapid, stable, and cost-effective production of virtually any recombinant protein and provides seamless integration of the bioproduction continuum, spanning discovery to commercialization. With global partners in 23 countries, 115 drug candidates in clinical development and four commercial products utilizing Selexis-generated cell lines, the Company empowers scientists and biopharmaceutical companies around the world to realize the full potential of their research.
With more than 250 global partners, KBI’s broad range of product development services, expertise in biophysical and biochemical characterization of proteins, and flexible business model makes KBI a CDMO of choice. KBI's contract development and manufacturing services are built on a strategic cornerstone of deep analytical capabilities. We are passionate in the belief that detailed protein characterization drives speed, benefiting clients at every stage of the development and manufacturing process.
Reach the Clinic Faster
With GENE to GMP, we are committed to our partners' satisfaction. By predictably getting cGMP material for your clinical study, we help you concentrate on the other critical components of your development program.
